Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2B | P29275 | 11/20 | 0.53 |
| ▸ | ADORA2A | P29274 | 8/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.52 |
| ▸ | MEN1 | O00255 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.52 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.52 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.52 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.52 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.52 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.52 |
| ▸ | ADORA1 | P30542 | 6/20 | 0.47 |
| ▸ | ADORA3 | P0DMS8 | 5/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5447101 | 0.79 | KDM4E (0.67) | ADORA2BADORA2AKDM4EMEN1ALDH1A1 | |
| SCHEMBL5449115 | 0.73 | MEN1 (0.45) | ADORA2BADORA2AKDM4EMEN1ALDH1A1 | |
| SCHEMBL5441255 | 0.73 | KDM4E (0.71) | ADORA2BADORA2AKDM4EMEN1ALDH1A1 | |
| SCHEMBL27304624 | 0.72 | ADORA2B (0.56) | ADORA2BADORA2AKDM4EMEN1ALDH1A1 | |
| SCHEMBL7037369 | 0.70 | ADORA2B (0.88) | ADORA2BADORA2AKDM4EMEN1ALDH1A1 | |
| SCHEMBL12648449 | 0.70 | ADORA2B (0.67) | ADORA2BADORA2AKDM4EMEN1ALDH1A1 | |
| SCHEMBL27311216 | 0.70 | ADORA2B (0.54) | ADORA2BADORA2AKDM4EMEN1ALDH1A1 | |
| SCHEMBL5440062 | 0.69 | KDM4E (0.64) | ADORA2BADORA2AKDM4EMEN1ALDH1A1 | |
| SCHEMBL5437071 | 0.69 | ALDH1A1 (0.64) | ADORA2BADORA2AKDM4EMEN1ALDH1A1 | |
| SCHEMBL661108 | 0.68 | ADORA2B (1.00) | ADORA2BADORA2AKDM4EMEN1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6946465-B2 | Immunosuppressive effects of pteridine derivatives | 4 AZA BIOSCIENCE NV (BE) | 2005-09-20 | — | — | US | claimed |
| US-20030236255-A1 | Immunosuppressive effects of pteridine derivatives | 4 AZA BIOSCIENCE NV (BE) | 2003-12-25 | — | — | US | claimed |
| US-6946465-B2 | Immunosuppressive effects of pteridine derivatives | 4 AZA BIOSCIENCE NV (BE) | 2005-09-20 | — | — | US | disclosed |
| US-20030236255-A1 | Immunosuppressive effects of pteridine derivatives | 4 AZA BIOSCIENCE NV (BE) | 2003-12-25 | — | — | US | disclosed |
| EP-1187615-A2 | IMMUNOSURPRESSIVE EFFECTS OF PTERIDINE DERIVATIVES | K.U. Leuven Research & Development (BE) | 2002-03-20 | — | — | EP | disclosed |
| WO-2000045800-A2 | IMMUNOSURPRESSIVE EFFECTS OF PTERIDINE DERIVATIVES | K.U. LEUVEN RESEARCH & DEVELOPMENT (BE) | 2000-08-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030236255-A1 | Immunosuppressive effects of pteridine derivatives | TPMT, FKBP5, RRP15 | ADORA2B 2693/4885ADORA2A 573/4885KDM4E 1278/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.